Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice.

Identification of the critical pathways involved in tumorigenesis should ultimately lead to the design of better anticancer agents that target specific components of the disrupted pathways. Murine models of spontaneous cancer in which tumor formation is dependent on defined genetic alterations provide a powerful test system for evaluating the therapeutic efficacy of pathway-specific antineoplastics. We have generated a conditional mouse model for retinoblastoma-dependent sporadic cancer that permits noninvasive monitoring of pituitary tumor development in live animals via in vivo bioluminescence imaging of luciferase expression. We show that the high sensitivity of bioluminescence imaging can be used for noninvasive detection of luciferase expression in pituitary glands from tumor-free animals and for in vivo quantitation of tumor burden over a large dynamic range. This mouse model permits longitudinal monitoring of tumor onset, progression, and response to therapy and may be used effectively for testing cancer prevention and treatment strategies based on therapeutics that specifically target the retinoblastoma pathway.

[1]  M. Ewen,et al.  The cell cycle and the retinoblastoma protein family , 1994, Cancer and Metastasis Reviews.

[2]  Philippe Soriano.  Generalized lacZ expression with the ROSA26 Cre reporter strain , 1999, Nature Genetics.

[3]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Peters,et al.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.

[5]  B. Hogan,et al.  Manipulating the mouse embryo: A laboratory manual , 1986 .

[6]  H. Shimada,et al.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Gallie,et al.  The retinoblastoma protein and the cell cycle. , 1992, Seminars in cancer biology.

[8]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[9]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[10]  A. Berns,et al.  Cre-mediated somatic site-specific recombination in mice. , 1997, Nucleic acids research.

[11]  S. Cherry,et al.  Quantification of target gene expression by imaging reporter gene expression in living animals , 2000, Nature Medicine.

[12]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[13]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.

[14]  C. Contag,et al.  Noninvasive assessment of tumor cell proliferation in animal models. , 1999, Neoplasia.

[15]  David K. Stevenson,et al.  Bioluminescent indicators in living mammals , 1998, Nature Medicine.

[16]  J. West.  Manipulating the Mouse Embryo . A Laboratory Manual, 2nd Edition. By Brigid Hogan, Rosa Beddington, Frank Costantini and Elizabeth Lacy. Cold Spring Harbor Laboratory Press 1994, 497 pages. Price $95. ISBN 0-87969-384-3.--- Either ISSN or Journal title must be supplied. , 1995 .

[17]  Anna Moore,et al.  In vivo magnetic resonance imaging of transgene expression , 2000, Nature Medicine.

[18]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[19]  W. Benedict,et al.  The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Berns,et al.  Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.

[21]  A. Berns,et al.  Developmental rescue of an embryonic‐lethal mutation in the retinoblastoma gene in chimeric mice. , 1994, The EMBO journal.

[22]  Jos Jonkers,et al.  A highly efficient ligand‐regulated Cre recombinase mouse line shows that LoxP recombination is position dependent , 2001, EMBO reports.

[23]  C. Contag,et al.  Visualizing the kinetics of tumor-cell clearance in living animals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Vooijs,et al.  Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse , 1998, Oncogene.

[25]  J. Beijnen,et al.  Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein , 1999, British Journal of Cancer.

[26]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[27]  W. Lee,et al.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.

[28]  S. Lowe,et al.  Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.

[29]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[30]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[31]  A. Bradley,et al.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis , 1992, Nature.